Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Jeske
Walter P
WP
Department of Thoracic-Cardiovascular Surgery, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL, USA.
Walenga
Jeanine M
JM
D000721:Ancrod / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000991:Antithrombins / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D000991:Antithrombins; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D006493:Heparin; D000721:Ancrod